Tourmaline Bio Surges 57.85 on $1.4B Novartis Deal as Volume Jumps 3346 to Rank 66th

On Sept. 9, 2025, , . , , .

The deal, announced earlier in the week, positions Tourmaline as a key player in the biotech sector. Novartis’s acquisition underscores the strategic value of biotech partnerships, particularly in leveraging advanced . This transaction aligns with broader of consolidation and innovation, bolstering investor confidence in the company’s future growth potential.

To robustly backtest a volume-based strategy, consider the following parameters: 1) Market universe selection (e.g., S&P 500), 2) Trade timing (open positions at day t+1 open), and 3) Weighting (equal-weighting with no transaction costs). The strategy involves ranking stocks by volume, entering positions at the next day’s open, and exiting at close. Adjustments to these parameters will refine the strategy’s effectiveness.